SFX by Ex Libris Inc.

Title:	Methodological aspects of the molecular and histological study of prostate cancer: Focus on PTEN
Source:	Methods [1046-2023] Ugalde Olano, Aitziber yr:2015

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Tomlins, Scott A. "The mutational landscape of lethal castration-resistant prostate cancer." Nature 487.7406 (2012): 239-243.
description	2.	Eritja, N. "Modeling glands with PTEN deficient cells and microscopic methods for assessing PTEN loss: Endometrial cancer as a model." Methods 77-7 (2015): 31-40.
description	3.	Shen, M. "Molecular genetics of prostate cancer: new prospects for old challenges." Genes & development 24.18 (2010): 1967-2000.
description	4.	Speak, Anneliese O. "A high-throughput in vivo screening method in the mouse for identifying regulators of metastatic colonization." Nature Protocols 12.12 (2017): 2465-2477.
description	5.	Baca, Sylvan C. "Punctuated evolution of prostate cancer genomes." Cell 153.3 (2013): 666-677.
description	6.	Barbieri, Christopher E. "Molecular genetics of prostate cancer: emerging appreciation of genetic complexity." Histopathology 60.1 (2012): 187-198.
description	7.	Shawana, S. "Differential expression of phophatase and tensin homologue in normal, hyperplastic and neoplastic endometrium." Journal of the Pakistan Medical Association (2014): 1103-8.
description	8.	Mahdi, H. "Germline PTEN, SDHB-D, and KLLN alterations in endometrial cancer patients with Cowden and Cowden-like syndromes: An international, multicenter, prospective study." Cancer 121.5 (2015): 688-96.
description	9.	Meegalla, Sanath K. "Structure-based optimization of a potent class of arylamide FMS inhibitors." Bioorganic & medicinal chemistry letters 18.12 (2008): 3632-4099.
description	10.	Farmer, H. "Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy." Nature 434.7035 (2005): 917-21.
description	11.	Bryant, Helen E. "Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase." Nature 447.7142 (2007): 346-7.
description	12.	Shen, M M M. "Molecular genetics of prostate cancer." Genes & development 14.19 (2000): 2410-34.
description	13.	Wang, K. "Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer." Nature Genetics 43.12 (2011): 1219-1223.
description	14.	Gao, W. "Androgen receptor as a therapeutic target." Advanced Drug Delivery Reviews 62.13 (2010): 1277-1284.
description	15.	Boss, D. "Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers." New England Journal of Medicine, The 361.2 (2009): 123-134.
description	16.	Tutt, A. "Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial." The Lancet 376.9737 (2010): 235-244.
description	17.	Gelmann, E. "Molecular biology of the androgen receptor." Journal of clinical oncology 20.13 (2002): 3001-3015.
description	18.	Saramäki, Outi R R. "The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer." Genes, chromosomes & cancer 45.7 (2006): 639-45.
description	19.	Ono, M. "Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting Drugs." Clinical cancer research 12.24 (2006): 7242-51.
description	20.	van der Weyden, Louise A. "Genome wide in vivo mouse screen data from studies to assess host regulation of metastatic colonisation." Scientific data. 4: 170129-170129.